Pharmaceutical composition for acute myocardial infarction

Abstract

The invention provides a pharmaceutical composition for acute myocardial infarction. The pharmaceutical composition is prepared from the following components in parts by weight: 14 to 20 parts of rhizoma gastrodiae, 12 to 15 parts of rhizoma pinelliae, 6 to 12 parts of poria cocos, 6 to 10 parts of rhizoma corydalis decumbentis, 3 to 8 parts of semen cuscutae, 2 to 6 parts of rhizoma dryopteris crassirhizomae, 2 to 8 parts of fructus forsythiae, 1 to 4 parts of dysosma versipellis, 1 to 3 parts of litsea cubeba, 0.5 to 2 parts of herba rabdosiae, 0.2 to 0.8 part of storax, 0.2 to 1 part of radix zanthoxyli, 0.1 to 0.4 part of cortex eucommiae, 0.1 to 0.3 part of fructus rosae laevigatae, 0.05 to 0.4 part of fructus corni, 0.05 to 0.2 part of semen lepidii, 0.1 to 0.2 part of herba lycopi and 0.1 to 0.2 part of honeysuckle stems Based on the compounding scheme, the pharmaceutical composition has a good treatment effect on acute myocardial infarction, can effectively expand blood vessels, rapidly dissolve thrombus and recover myocardial blood supply, and besides, relieves infarction focus caused by myocardial ischemia. When the composition is orally taken, the rescue success rate of acute myocardial infarction can be remarkably increased, and the occurrence rate of serious complications such as arrhythmia, heart failure and cardiac shock can be reduced.

Description

technical field [0001] The invention relates to the technical field of pharmacy, and further relates to the development of novel pharmaceutical compositions, in particular to a pharmaceutical composition for acute myocardial infarction. Background technique [0002] Acute myocardial infarction, also known as acute myocardial infarction, is myocardial necrosis caused by acute and persistent coronary ischemia and hypoxia. Clinically, there are often severe and persistent substernal pains, which cannot be completely relieved by rest and nitrates, accompanied by increased serum myocardial enzyme activity and progressive ECG changes, which may be complicated by arrhythmia, shock or heart failure, often life-threatening. The disease is most common in Europe and the United States, and about 1.5 million people in the United States suffer from myocardial infarction every year. China has shown a clear upward trend in recent years, with at least 500,000 new cases each year and at leas...

AI Technical Summary

Problems solved by technology

[0006] The present invention aims at the technical defects of the prior art, and provides a pharmaceutical composition for acute myocardial infarction, so as to solve the technical problem that the success rate of conventional drugs for acute myocardial infarction is relatively low.